论文部分内容阅读
目的观察降纤酶联合低分子肝素治疗急性进展型脑梗死的临床疗效。方法将94例急性进展型脑梗死患者随机分为:治疗组33例,用降纤酶静脉滴注,同时使用低分子肝素脐周皮下注射;对照A组30例,用降纤酶静脉滴注;对照B组31例,用低分子肝素脐周皮下注射。结果治疗组神经功能缺损程度明显改善,与两组对照组相比,差异有统计学意义(P<0.05);治疗组总有效率高于两组对照组,差异有统计学意义(P<0.05);治疗14d后,治疗组与对照A组血纤维蛋白原含量均显著下降(P<0.01);治疗组4例出现注射部位皮下瘀斑,均自行消退,无一例出现颅内出血的副作用。结论降纤酶联合低分子肝素治疗急性进展型脑梗死,能有效促进神经功能缺损程度的改善,提高治疗总有效率,且具有良好的安全性。
Objective To observe the clinical effect of defibrase combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction. Methods 94 patients with acute progressive cerebral infarction were randomly divided into: treatment group, 33 cases, with defibrase infusion, while using low molecular weight heparin umbilical subcutaneous injection; control group A 30 cases, with defibrase intravenous infusion ; Control group B 31 cases, with low molecular weight heparin umbilical subcutaneous injection. Results Compared with the control group, the degree of neurological deficit in the treatment group was significantly improved (P <0.05). The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05) ). After 14 days of treatment, the content of fibrinogen in treatment group and control group A decreased significantly (P <0.01). In the treatment group, 4 cases had subcutaneous ecchymosis at the injection site, both of which subsided spontaneously. None of them had side effects of intracranial hemorrhage. Conclusion Defibrase combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction can effectively improve the degree of neurological deficits and improve the total effective rate, and has good safety.